Funder
São Paulo Research Foundation-FAPESP
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Disov. 2016;15:385–403.
2. FDA AVASTIN® Prescribing Information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s332lbl.pdf. Accessed on 05 Oct 2020.
3. Ellis LM, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov. 2005;3:995–996.
4. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186–93.
5. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807–15.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献